Recommendation ID
There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for people who have cancer and experience an acute pulmonary embolism or deep vein thrombosis. As in NICE technology appraisal guidance 261 it is recommended that further research should be carried out.
Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Date issued
June 2013

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 15/07/2013